Isoindoline Compounds for Refractory Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy, radiation therapy, and hormonal therapy, are associated with significant side effects and drug resistance, making them ineffective for refractory cancers and other diseases characterized by undesired angiogenesis or mediated by PDE 4.
Innovation Solution
Development of novel isoindoline compounds and their pharmaceutically acceptable salts, solvates, prodrugs, and stereoisomers for administering therapeutically or prophylactically to treat, prevent, or manage cancer and other diseases associated with undesired angiogenesis or mediated by PDE 4, either alone or in combination with conventional therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (chemotherapy, radiation therapy, hormonal therapy) are used to treat cancer, then cancer cells can be eradicated, but significant side effects and drug resistance occur
Solution Approach 1:
The patent changes the chemical parameters by developing novel isoindoline compounds with specific molecular structures (formula I and II) that differ from conventional therapies. These compounds have modified pharmacological properties that reduce side effects while maintaining anti-cancer activity, directly addressing the contradiction between effectiveness and harmful effects
Solution Approach 2:
The patent creates composite therapeutic approaches by combining isoindoline compounds with conventional therapies in combination regimens. This composite strategy leverages the mechanisms of multiple agents to overcome drug resistance while managing side effects through synergistic or additive effects
2Reliability
If conventional therapies are used for refractory cancers, then treatment can be attempted, but the therapies become ineffective due to drug resistance
Solution Approach 1:
The patent inverts the conventional approach by using isoindoline compounds that target alternative pathways or mechanisms not affected by traditional drug resistance. Instead of trying to overcome resistance to conventional agents, the invention uses fundamentally different chemical structures that bypass the resistance problem entirely
Solution Approach 2:
The isoindoline compounds exhibit multi-functional activity, targeting multiple pathways involved in cancer progression including angiogenesis inhibition and direct anti-proliferative effects. This multi-functionality allows the single compound class to address various mechanisms of resistance simultaneously
3Reliability
If new cancer treatments are developed to overcome drug resistance, then effectiveness against refractory cancer improves, but treatment complexity and cost increase
Solution Approach 1:
The patent segments the anti-cancer activity into distinct functional components within the isoindoline molecular structure (substituents at positions R1-R6, R7-R12). This modular molecular design allows for systematic optimization of activity while maintaining a relatively simple core structure, reducing overall treatment complexity
Data Source
AI summary
Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.